Zanfirescu Anca, Avram Ionela, Gatea Florentina, Roșca Răzvan, Vamanu Emanuel
Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Department of Genetics, University of Bucharest, 36-46 Bd. M. Kogalniceanu, 5th District, 050107 Bucharest, Romania.
Life (Basel). 2023 Dec 30;14(1):68. doi: 10.3390/life14010068.
The increasing incidence of diabetes has prompted the need for new treatment strategies, including natural products that reduce glycemia values. This work examined the in vitro and in vivo antihyperglycemic effects of new metabiotics derived from extracts. The metabiotics were obtained from 100% , and two other products, CARDIO and GLYCEMIC, from Anoom Laboratories SRL, which contain other microbial species related to . Our in vitro investigations (simulations of the microbiota of patients with type 2 diabetes (T2D)) demonstrated that extracts modulate the microbiota, normalizing its pattern. The effects were further tested in vivo, employing a mouse model of T2D. The tested extracts decreased glycemia values compared to the control and modulated the microbiota. The metabiotics had positive effects on T2D in vitro and in vivo, suggesting their potential to alleviate diabetes-associated microbiota dysbiosis.
糖尿病发病率的不断上升促使人们需要新的治疗策略，包括使用能降低血糖值的天然产物。这项研究考察了从提取物中获得的新型后生元的体外和体内降血糖作用。这些后生元是从100%[具体物质]中获得的，另外两种产品CARDIO和GLYCEMIC来自Anoom Laboratories SRL，它们含有与[相关微生物种类]相关的其他微生物。我们的体外研究（模拟2型糖尿病（T2D）患者的微生物群）表明，[提取物名称]提取物可调节微生物群，使其模式正常化。在T2D小鼠模型中对这些作用进行了进一步的体内测试。与对照组相比，测试的提取物降低了血糖值并调节了微生物群。这些后生元在体外和体内对T2D均有积极作用，表明它们具有缓解糖尿病相关微生物群失调的潜力。
